Old Articles: <Older 8491-8500 Newer> |
|
Pharmaceutical Executive December 1, 2012 Hager & Temme |
Germany's Price Reform Revolution At two years and counting, what's the secret of success in negotiating pricing under the new Act on Reform of the Market for Pharmaceutical Products legislation? |
Pharmaceutical Executive December 1, 2012 Torrey et al. |
Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual. |
Pharmaceutical Executive December 1, 2012 |
Big Data, Bigger Ideas How to stop worrying and learn to love the data. Let's face it and let's be brave about it: the balance of power has shifted permanently from the marketers to the marketed. |
Pharmaceutical Executive December 1, 2012 Jill Wechsler |
Obamacare, Innovation and Pricing Tax and budget decisions will shape the healthcare market and drug research and regulation. |
Pharmaceutical Executive December 1, 2012 Ben Comer |
Top Medical Innovations for 2013 The author profiles 10 innovative technologies designated as new and revolutionary tools for the treatment of disease and disability, such as neuromodulation for cluster and migraine headache. |
Pharmaceutical Executive December 1, 2012 William Looney |
2012: Year of Record The calendar says its wrap-up time, not just for gifts but for some of the trends that shaped the industry for good or bad in the year 2012. |
Chemistry World December 10, 2012 Andrew Turley |
Pfizer's lost gold A stash of gold dust bought for $700,000 last year has gone missing from a Pfizer lab in St Louis, Missouri. |
Information Today December 10, 2012 |
Thomson Reuters Announces Cortellis for Clinical Trials Intelligence Scheduled for release in early 2013, this capability will provide drug development and clinical professionals with the critical information. |
Chemistry World December 6, 2012 Andrew Turley |
Return on drug R&D dropping The pharma industry is getting less and less return on investment in R&D, according to a report. But the trend seems to be bottoming out and -- on a more positive note -- there are more compounds going into late stage development. |
Chemistry World December 6, 2012 Andrew Turley |
Baxter to pay $4bn for dialysis firm US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion |
<Older 8491-8500 Newer> Return to current articles. |